Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShah, Dhruvin R-
dc.contributor.authorModh, Rahul P-
dc.contributor.authorDesai, Dhara D-
dc.contributor.authorChikhalia, Kishor H-
dc.identifier.issn0975-0975(Online); 0376-4710(Print)-
dc.description.abstractTo cure multi-drug resistant problem, a series of quinazolinone based 5-arylidene-2- ( (2- (2-methyl-4-oxoquinazolin-3- (4H)-yl) ethyl) amino) thiazol-4 (5H)-one 6a-j have been synthesized. Quinazoline and styryl thiazolidinones have been clubbed through ethyl linkage to get hybrid molecule. Final synthesized compounds are screened for their in vitro antimicrobial activity against bacterial and fungal strains i.e two Gram-positive bacteria (S. aureus, B. cereus), six Gram-negative bacteria (E. coli, P. aeruginosa, K. pneumoniae, S. typhi, P. vulgaris, and S. flexneria) and two fungal species (A. niger, and C. albicans) using broth dilution technique. In vitro antimycobacterial efficacy has also been studied against Mycobacterium tuberculosis H37Rv using BACTEC MGIT method. Antituberculosis results have pointed towards the equal potency of the lead compounds (MIC= 6.25 µg/mL) in comparison to the standard Pyrazinamide drug. Though compounds bearing-ortho and-meta chloro substitution have shown 99% strain inhibition, MIC of 6.25 µg/mL has proved its superiority over >6.25 µg/mL MIC. All the final synthesized compounds have been confirmed by FT-IR, 1H and 13C NMR, mass and elemental analysis. en_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-B Vol.53B(09) [September 2014]en_US
dc.titleNovel quinazolinone-thiazolidinone hybrid: Design, synthesis and in vitro antimicrobial and antituberculosis studiesen_US
Appears in Collections:IJC-B Vol.53B(09) [September 2014]

Files in This Item:
File Description SizeFormat 
IJCB 53B(9) 1169-1177.pdf132.42 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.